Fagan Associates Inc. raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 42.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,923 shares of the biopharmaceutical company's stock after purchasing an additional 3,832 shares during the period. Regeneron Pharmaceuticals accounts for approximately 1.5% of Fagan Associates Inc.'s investment portfolio, making the stock its 18th biggest position. Fagan Associates Inc.'s holdings in Regeneron Pharmaceuticals were worth $9,205,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $26,000. Fairfield Financial Advisors LTD bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $37,000. Private Wealth Management Group LLC increased its position in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after buying an additional 39 shares in the last quarter. Finally, Truvestments Capital LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $39,000. 83.31% of the stock is owned by institutional investors.
Regeneron Pharmaceuticals Stock Performance
Shares of NASDAQ:REGN traded up $4.31 during mid-day trading on Friday, reaching $700.33. The company had a trading volume of 724,688 shares, compared to its average volume of 911,880. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market cap of $76.56 billion, a price-to-earnings ratio of 18.29, a PEG ratio of 2.30 and a beta of 0.08. The company's 50-day moving average price is $700.02 and its 200-day moving average price is $886.33. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $11.86 EPS. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%.
Analyst Ratings Changes
REGN has been the subject of a number of research analyst reports. UBS Group lowered Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their target price for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. TD Cowen cut their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. Bernstein Bank cut their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a research note on Wednesday, February 5th. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 4th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.
View Our Latest Stock Analysis on REGN
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
